Skip to main content
logo
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.00
+0.13 (2.21%)
Apr 8, 2026, 9:42 AM EDT - Market open

Xeris Biopharma Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
291.85203.07163.91110.2549.59
Revenue Growth (YoY)
43.72%23.89%48.68%122.32%142.67%
Cost of Revenue
42.5736.8328.6522.6313.32
Gross Profit
249.28166.24135.2787.6136.27
Selling, General & Admin
182.37163.48146.1137.75125.72
Depreciation & Amortization Expenses
10.8410.8410.8410.840.55
Research & Development
31.1725.5622.3420.9725.16
Total Operating Expenses
224.38199.88179.28169.55151.43
Operating Income
24.9-33.65-44.01-81.94-115.16
Interest Income
4.745.324.752.580.31
Interest Expense
-29.08-30.49-26.61-14.1-7.18
Other Non-Operating Income (Expense)
-1.712.36-2.62-0.7
Total Non-Operating Income (Expense)
-24.34-23.46-19.49-14.14-7.57
Pretax Income
0.55-57.1-63.5-96.08-122.73
Provision for Income Taxes
--2.27-1.25-1.42-
Net Income
0.55-54.84-62.26-94.66-122.73
Net Income to Common
0.55-54.84-62.26-94.66-122.73
Shares Outstanding (Basic)
16014713813679
Shares Outstanding (Diluted)
17314713813679
Shares Change (YoY)
17.69%6.61%1.51%71.62%85.32%
EPS (Basic)
0.00-0.37-0.45-0.70-1.55
EPS (Diluted)
0.00-0.37-0.45-0.70-1.55
Shares Outstanding
166.22149.43138.13136.27124.87
Free Cash Flow
27.93-37.85-49.29-103.42-96.62
Free Cash Flow Per Share
0.16-0.26-0.36-0.76-1.22
Gross Margin
85.41%81.86%82.52%79.47%73.14%
Operating Margin
8.53%-16.57%-26.85%-74.32%-232.22%
Profit Margin
0.19%-27.00%-37.98%-85.86%-247.48%
FCF Margin
9.57%-18.64%-30.07%-93.80%-194.84%
EBITDA
37.05-21.58-31.68-69.7-113.28
EBITDA Margin
12.70%-10.62%-19.33%-63.22%-228.43%
EBIT
24.9-33.65-44.01-81.94-115.16
EBIT Margin
8.53%-16.57%-26.85%-74.32%-232.22%
Effective Tax Rate
0.00%3.97%1.97%1.48%0.00%
Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q